Global pharma giants remain committed to investing in Shanghai

Pharma companies remain undaunted by the disruption brought by the pandemic

And are maintaining their investment in China's booming health-care market with various

New partnerships and collaborations spanning a wide range of fields.

Siemens Healthineers said it plans to to further enhance the scale

Of localization and expand product listings to be made in China to better suit local demands.

In addition to existing local products, some of its high-end product lines like magnetic resonance facilities,

MRI scanners and ultrasound systems are now also being produced locally.